Company intelligence / Profile preview
Sollis Therapeutics
Columbus, Ohio, United Statessollistx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
A Phase 3 randomized, double-blind, sham-controlled study evaluating STX-015 showed safety and efficacy in treating low back and leg pain from sciatica; however, this trial was terminated according to clinical trial records. Another long-term safety follow-up study was completed successfully.
- Therapeutic areas
- OncologyPsychiatryNeurology
- Modalities
- novel interventional non-steroid, non-opioid analgesic therapeuticsclonidine micropellets
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sollis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sollis Therapeutics.